BioSpace News Archive

Nucleus Research has opened submissions for the 2021 ROI Awards.

Echosens, a high-technology company offering the FibroScan family of products, is pleased to announce that it has been chosen among the top 12 innovative companies for PM360’s 9th annual Innovations Issue, which focused on the healthcare industry’s most innovative companies, startups, divisions, products, services and strategies of 2020.

Boragen Inc., a world-leading boron-based discovery platform, today announced that it has added Dr. Brian Metcalf to its Scientific Advisory Board.

Dyadic International, Inc. a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs, and improve the performance of vaccines, drugs and other biological products at flexible commercial scales, today announced a fully funded collaboration with TurtleTree Scientific to develop a number of recombinant protein growth factors

Rithem Life Sciences, a Wilmington, Delaware-based medical device company and developer of safe and efficacious life-saving portable products, has announced the formation of its Board of Directors.

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has completed full enrollment of the Phase 3 ELEVATE UC 52 trial evaluating the safety and efficacy of etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, in participants with moderately-to-severely active ulcerative colitis

Ocugen, Inc., (NASDAQ: OCGN), and Bharat Biotech, a global leader in vaccine innovation, today announced they have entered into a definitive agreement to co-develop, supply, and commercialize Bharat Biotech’s COVAXIN™, an advanced stage whole-virion inactivated COVID-19 vaccine candidate, for the United States market.

Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the German Institute for the Hospital Remuneration System(“InEK”) has awarded the Neovasc Reducer™ (“Reducer”), a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation once again for 2021.

Three Lakes Foundation announces it is collaborating with Mayo Clinic to increase awareness of pulmonary fibrosis symptoms; improve an understanding of the current diagnostic journey; and develop a remote diagnostic tool that connects patients with appropriate healthcare resources at an earlier and more treatable phase of their illness.

New York-based Xylyx Bio, a leader in predictive disease models and tissue-specific extracellular matrix (ECM) products, and Cell&Soft SAS, a French biotech company specializing in innovative soft cell culture plates, today announced positive preliminary results, reaching a key milestone in their partnership to develop more physiologically relevant in vitro cellular models for cell-based assays in oncology.